sorafenib has been researched along with zm 336372 in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (zm 336372) | Trials (zm 336372) | Recent Studies (post-2010) (zm 336372) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 27 | 0 | 11 |
| Protein | Taxonomy | sorafenib (IC50) | zm 336372 (IC50) |
|---|---|---|---|
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 100 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.0603 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.57 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.23 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.18 | |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | 2 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 1.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gray, NS; Liu, Y | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Dotterweich, J; Einsele, H; Lohmeyer, J; Nerreter, T; Seggewiss-Bernhardt, R | 1 |
3 other study(ies) available for sorafenib and zm 336372
| Article | Year |
|---|---|
Rational design of inhibitors that bind to inactive kinase conformations.
Topics: Binding Sites; Drug Design; Humans; Models, Molecular; Phosphotransferases; Protein Kinase Inhibitors; Protein Structure, Tertiary | 2006 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.
Topics: Apoptosis; Benzamides; Cell Degranulation; Cell Line; Cytokines; Extracellular Signal-Regulated MAP Kinases; Humans; Killer Cells, Natural; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; Sunitinib | 2018 |